135 related articles for article (PubMed ID: 34978843)
1. Effects of double combinations of enterovirus replication inhibitors against Coxsackie B viruses.
Stoyanova A; Galabov AS
Acta Virol; 2021; 65(4):411-419. PubMed ID: 34978843
[TBL] [Abstract][Full Text] [Related]
2. Anti-enteroviral triple combination of viral replication inhibitors: activity against coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Pürstinger G; Dobrikov G; Dimitrov V; Philipov S; Galabov AS
Antivir Chem Chemother; 2015 Dec; 24(5-6):136-147. PubMed ID: 27815331
[TBL] [Abstract][Full Text] [Related]
3. Effect of consecutive alternating administration (CAA) of a triple anti-enteroviral combination on Coxsackievirus B1 neuroinfection in mice.
Stoyanova A; Nikolova I; Galabov AS
Antiviral Res; 2015 Sep; 121():138-44. PubMed ID: 26196747
[TBL] [Abstract][Full Text] [Related]
4. Consecutive alternating administration as an effective anti-coxsackievirus B3 in vivo treatment scheme.
Stoyanova A; Galabov AS
Arch Virol; 2021 Jul; 166(7):1869-1875. PubMed ID: 33877422
[TBL] [Abstract][Full Text] [Related]
5. Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3.
Stoyanova A; Galabov AS
Pathog Dis; 2020 Nov; 78(9):. PubMed ID: 33090201
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the Consecutive Alternating Administration Course of a Triple Antiviral Combination in Coxsackievirus B3 Infections in Mice.
Vassileva-Pencheva R; Galabov AS
Drug Res (Stuttg); 2016 Dec; 66(12):639-643. PubMed ID: 27552486
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5.
Lane TR; Fu J; Sherry B; Tarbet B; Hurst BL; Riabova O; Kazakova E; Egorova A; Clarke P; Leser JS; Frost J; Rudy M; Tyler KL; Klose T; Volobueva AS; Belyaevskaya SV; Zarubaev VV; Kuhn RJ; Makarov V; Ekins S
Antiviral Res; 2023 Aug; 216():105654. PubMed ID: 37327878
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Peptides Targeting the Helicase Activity of Enterovirus Nonstructural Protein 2C.
Fang Y; Wang C; Wang C; Yang R; Bai P; Zhang XY; Kong J; Yin L; Qiu Y; Zhou X
J Virol; 2021 May; 95(12):. PubMed ID: 33789997
[TBL] [Abstract][Full Text] [Related]
9. A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Sioofy-Khojine AB; Honkimaa A; Hyöty H
Diabet Med; 2020 Nov; 37(11):1849-1853. PubMed ID: 31705692
[TBL] [Abstract][Full Text] [Related]
10. Activity of pleconaril against enteroviruses.
Pevear DC; Tull TM; Seipel ME; Groarke JM
Antimicrob Agents Chemother; 1999 Sep; 43(9):2109-15. PubMed ID: 10471549
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Combination Approach as a Perspective to Combat Enterovirus Infections.
Galabov AS; Nikolova I; Vassileva-Pencheva R; Stoyanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):91-9. PubMed ID: 27442375
[TBL] [Abstract][Full Text] [Related]
12. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.
Schmidtke M; Wutzler P; Zieger R; Riabova OB; Makarov VA
Antiviral Res; 2009 Jan; 81(1):56-63. PubMed ID: 18840470
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-enterovirus activity of new analogues of MDL-860.
Dobrikov GM; Slavchev I; Nikolova I; Stoyanova A; Nikolova N; Mukova L; Nikolova R; Shivachev B; Galabov AS
Bioorg Med Chem Lett; 2017 Oct; 27(19):4540-4543. PubMed ID: 28870395
[TBL] [Abstract][Full Text] [Related]
14. The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants.
Ianevski A; Frøysa IT; Lysvand H; Calitz C; Smura T; Schjelderup Nilsen HJ; Høyer E; Afset JE; Sridhar A; Wolthers KC; Zusinaite E; Tenson T; Kurg R; Oksenych V; Galabov AS; Stoyanova A; Bjørås M; Kainov DE
Antiviral Res; 2024 Apr; 224():105842. PubMed ID: 38417531
[TBL] [Abstract][Full Text] [Related]
15. Antiviral treatment of Coxsackie B virus infection in human pancreatic islets.
Berg AK; Olsson A; Korsgren O; Frisk G
Antiviral Res; 2007 Apr; 74(1):65-71. PubMed ID: 17239967
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
17. The Evolution of Pleconaril: Modified
Volobueva A; Egorova A; Galochkina A; Ekins S; Zarubaev V; Makarov V
Molecules; 2020 Mar; 25(6):. PubMed ID: 32188089
[TBL] [Abstract][Full Text] [Related]
18. In-vitro antiviral activity of doxepin hydrochloride against group B coxsackievirus.
Yang Y; Liu G; Jia J; Zhong J; Yan R; Lin X; Zheng K; Zhu Q
Virus Res; 2022 Aug; 317():198816. PubMed ID: 35598772
[TBL] [Abstract][Full Text] [Related]
19. New class of early-stage enterovirus inhibitors with a novel mechanism of action.
Ma Y; Abdelnabi R; Delang L; Froeyen M; Luyten W; Neyts J; Mirabelli C
Antiviral Res; 2017 Nov; 147():67-74. PubMed ID: 28993161
[TBL] [Abstract][Full Text] [Related]
20. Severe Coxsackie virus B infection in preterm newborns treated with pleconaril.
Bauer S; Gottesman G; Sirota L; Litmanovitz I; Ashkenazi S; Levi I
Eur J Pediatr; 2002 Sep; 161(9):491-3. PubMed ID: 12200608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
